Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30129098 | 1.00 | TSHR (0.45) | TSHRALOX15IDO1SMN1; SMN2CCR1 | |
| SCHEMBL24878556 | 0.92 | ALOX15 (0.44) | TSHRALOX15IDO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30129114 | 0.92 | ALOX15 (0.44) | TSHRALOX15IDO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30129203 | 0.89 | ALOX15 (0.43) | ALOX15IDO1TP53KDM4EMAPT | |
| SCHEMBL24877857 | 0.89 | ALOX15 (0.43) | ALOX15IDO1TP53KDM4EMAPT | |
| SCHEMBL24878451 | 0.87 | ALOX15 (0.50) | ALOX15IDO1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30128971 | 0.87 | ALOX15 (0.50) | ALOX15IDO1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24878014 | 0.87 | ALOX15 (0.47) | ALOX15IDO1SMN1; SMN2CCR1ALDH1A1 | |
| SCHEMBL24877871 | 0.87 | ALOX15 (0.47) | TSHRALOX15IDO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24878401 | 0.87 | CCR1 (0.44) | TSHRALOX15CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | TSHR 3557/4885ALOX15 633/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.